WO2011141454A1 - Wundauflage - Google Patents
Wundauflage Download PDFInfo
- Publication number
- WO2011141454A1 WO2011141454A1 PCT/EP2011/057491 EP2011057491W WO2011141454A1 WO 2011141454 A1 WO2011141454 A1 WO 2011141454A1 EP 2011057491 W EP2011057491 W EP 2011057491W WO 2011141454 A1 WO2011141454 A1 WO 2011141454A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- wound
- wound dressing
- dressing according
- suction
- rinsing body
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00051—Accessories for dressings
- A61F13/00063—Accessories for dressings comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/06—Bandages or dressings; Absorbent pads specially adapted for feet or legs; Corn-pads; Corn-rings
- A61F13/064—Bandages or dressings; Absorbent pads specially adapted for feet or legs; Corn-pads; Corn-rings for feet
- A61F13/069—Decubitus ulcer bandages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00089—Wound bandages
- A61F2013/00217—Wound bandages not adhering to the wound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00089—Wound bandages
- A61F2013/00246—Wound bandages in a special way pervious to air or vapours
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00727—Plasters means for wound humidity control
- A61F2013/00731—Plasters means for wound humidity control with absorbing pads
- A61F2013/00744—Plasters means for wound humidity control with absorbing pads containing non-woven
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00727—Plasters means for wound humidity control
- A61F2013/00748—Plasters means for wound humidity control with hydrocolloids or superabsorbers
- A61F2013/00753—Plasters means for wound humidity control with hydrocolloids or superabsorbers superabsorbent fabric of cloth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00855—Plasters pervious to air or vapours
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00902—Plasters containing means
- A61F2013/0091—Plasters containing means with disinfecting or anaesthetics means, e.g. anti-mycrobic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
- A61L2300/206—Biguanides, e.g. chlorohexidine
Definitions
- the invention relates to a wound dressing for wound treatment in a moist or wet-moist environment, with a nonwoven-based suction / rinsing, is distributed in the superabsorbent material, wherein the suction / rinsing body manufacturer with a salt-containing aqueous solution, in particular Ringer's solution, preferably until for saturation, is acted upon, and with a covering forming the outer visible sides of the wound dressing, wherein an evaporation-inhibiting film layer can be provided on the side of the suction / rinsing body facing away from the wound.
- Compressive wound dressing which can be applied to a wound or can also be used to stamp out deep wounds.
- the suction / rinsing body is preferably supplied by the manufacturer to saturation with a salt-containing aqueous solution containing the
- the change interval time ie the time of use of a wound dressing until the next dressing change, should be at least 24 h, with efforts to increase the change interval time,
- the present invention has for its object to improve a wound dressing of the type described above with a view to optimizing the wound conditioning, in particular with regard to a potentially prolonged change interval time.
- the aqueous solution is dissolved at a pH of 4 to 7.5 of a typical moist or wet-wet one
- Wound-milieu cationic substance with antimicrobial action includes that of negative groups of the anionic superabsorbent
- Wound milieu has an effect, since in the liquid exchange during operation of the absorbent / rinsing body fluid from the antimicrobial optimal
- Wound secretions / exudates with germs can reach the absorbent / rinsing body to a greater extent and be treated there antimicrobially.
- the term partial and structured applied coating implies that this is not a continuous coating, but a porous coating, as can be realized for example by dots, islands, lines, stripes or other coherent or non-contiguous structures.
- the anionic superabsorbent material is a polymer, in particular an at least partially crosslinked polymer, in particular based on polyacrylate.
- the anionic superabsorbent material is a polysaccharide, such as starch, or a polysaccharide derivative, for example
- the cationic substance with antimicrobial effect may be, for example, substances with amino or imino groups, which are cationically charged in a solution having a pH of 4 to 7.5.
- the cationic substance may be antimicrobially active metal cations, in particular silver cations, for example a complex of 1-vinyl-2-pyrrolidone with silver cations.
- Particularly suitable cationic substances with antimicrobial action are biguanide derivatives such as chlorhexidine or polybiguanides, such as polyethylene biguanide (PEB),
- PTMB Polytetramethylene biguanide
- PEHMB Polyethylene hexamethylene biguanides
- polyhexamethylene biguanide PHMB or polyhexanide
- Polyhexamethyleneguanidines PHMG
- quaternary ammonium compounds such as benzalkonium chloride or cetylpyridinium chloride
- triazines such as 1 - (3-chloroallyl) -3,5,7-triaza-1-azoniaadamantane chloride or the ammonium compound taurolidine.
- the concentration of the antiseptic-acting additive in the aqueous solution, which is then used to activate the dry suction / rinsing body is preferably 0.06 to 0.20 wt .-%, in particular 0.08 to 0.15 wt. -%, in particular 0.10 - 0.15 wt .-% (based on the aqueous solution before activating the suction / Spül stressess).
- superabsorbent material ensures that this substance largely or largely within the operation of the wound dressing within the Suction / rinsing remains. This can be done by means of the Hemmhoftests
- Hemmhoftests can be visually checked whether spill out of a test body germicidal substances in substantial amount or not. When they fail, they kill or hinder the growth of so-called colony forming units in an environment of the test body, which can be visually determined by inspection of the test body and its surroundings. If no such environment can be detected, ie no zone of inhibition, this means that no test substances have leaked any significant amount of the growth of the colonies.
- the wound dressing is further characterized in that leakage of cationic substance with antimicrobial effect from the wound dressing is visually undetectable when the inhibition test is carried out. This means that a drag yard is visually undetectable when performing the test described below.
- a wound dressing of the type in question here is placed as a test body on a previously prepared agar plate.
- a wound dressing of the type in question here is placed as a test body on a previously prepared agar plate.
- an 8.5 cm diameter agar plate was used, each containing 15 ml of casein peptone soy peptone agar (concentration of casein peptone soya peptone: 40 g / l).
- Agar plate was 100 ⁇ of a staphylococcus aureus ATCC 6538
- Germ suspension (about 5 x 10 6 colony forming units / ml) with a cotton swab and streaked for 10 to 15 min. dried. After drying the seed suspension with closed lid of the sterilized, but cooled to room temperature test body in the form of the wound dressing to be tested on the agar plate with the
- the plate is then incubated upright for 18 h at 35 ° C. Thereafter, the agar dish became visually after the formation of an inhibition zone examined.
- composition of the absorbent / rinsing body may conveniently comprise: a superabsorbent material of the abovementioned type in an amount of 120-170 g / m 2 , cellulosic fibers in an amount of 120-170 g / m 2, and in particular thermoplastic fibers in an amount of 5 - 18 g / m z .
- a superabsorbent material of the abovementioned type in an amount of 120-170 g / m 2
- cellulosic fibers in an amount of 120-170 g / m 2
- thermoplastic fibers in an amount of 5 - 18 g / m z .
- the absorbent / rinsing body may consist of the abovementioned components (and additionally the salt-containing aqueous solution).
- the nonwoven fabric is preferably one
- Polyolefin nonwoven fabric in particular a polypropylene nonwoven fabric.
- the wrapping on the wound-facing side of the wound dressing may advantageously be a textile sheet material, such as a knitted fabric, a knitted fabric or fabric, in particular of polyolefin, in particular of polypropylene.
- a textile sheet material such as a knitted fabric, a knitted fabric or fabric, in particular of polyolefin, in particular of polypropylene.
- Coating in the form of silicone on a textile sheet material, as previously mentioned, is applied, so there is a special in terms of flexibility, conformability and effectiveness
- Outside of the envelope is preferably 0.03 - 0.5 mm, in particular 0.1 - 0.4 mm, 0.1 - 0.3 mm, in particular 0.1 -0.2 mm.
- Coating preferably has a dimension in at least one plane direction of at most 4 mm, in particular of at most 3 mm, and more particularly from 1 to 3 mm, in particular from 2 to 3 mm.
- each other is preferably at least 1 mm and at most 5 mm.
- cellulosic fibers preferably air-laid cellulosic fibers or preferably air-laid
- thermoplastic fibers in particular polyolefin fibers, in particular polypropylene or
- Polypropylene / polyethylene fibers which preferably form the entire fiber base of the absorbent / rinsing body.
- the proportion of the thermoplastic fibers of such a fiber mixture is preferably only about 5-10% of the proportion of cellulosic fibers.
- Removed outer packaging It has a nonwoven-based absorbent / rinsing body with superabsorbent material, in particular Favor pac 300 from Evonik Stockhausen GmbH, and typically cellulosic fibers and possibly also thermoplastic fibers.
- the wound dressing 20 was activated with saline-containing aqueous solution, in particular Ringer's solution. This wound dressing 20 is then wound on its side facing the wound (reference numeral 8 in FIG. 1) to a water vapor impermeable one
- Edge region 24 is overlapped with a film 26 and thus fixed against the substrate (simulated application of the wound dressing).
- a film 26 (for example, the trademark Opsite flexifix) is spread over the wound dressing 20, and it is centrally cut, as shown in Figure 2, an opening 28 in the cover 26, so that the largest part of the surface 30 of the wound dressing 20 Environment is exposed and only the peripheral edge region 24 with 5mm width through the
- Covering foil 26 remains covered. Thus, the majority of the
- Weight difference observation can then be the evaporation rate in g / 24 h or g / 24h cm 2 are given.
- the latter size is a surface-specific evaporation rate related to the area unit of the exposed area.
- FIG. 1 shows a highly schematic sectional view of a wound dressing according to the invention
- Figure 2 shows the arrangement for carrying out the test for determining the
- FIG. 3 shows the result of measurements.
- Figure 1 shows in section a wound dressing 2. It comprises a suction / rinsing body 4 on nonwoven fabric.
- This fiber base is a preferred blend of airlaid cellulosic (pulp) and polypropylene or polypropylene / polyethylene fibers.
- Superabsorbent polymer materials (SAP) in particulate form or in fiber form are admixed as homogeneously as possible with this fiber mixture, the SAP proportion in the total mass of the absorbent / rinsing body preferably being 40-50% by weight.
- the average particle size of the SAP particles is, for example, 150 to 850 ⁇ m (for example, the polyacrylate brand Favor pac 300 from Evonik Stockhausen GmbH).
- the suction / rinsing body 4 is surrounded by an outer side of the wound dressing forming sheath 6, which is wound-facing
- Envelope layer 8 and a wound-facing envelope layer 10 is formed, which are connected to each other at the edge. In the wounded
- Coating layer 8 is preferably a knitted fabric, preferably made of polypropylene, wherein a woven or knitted fabric would also be conceivable in an advantageous manner, that is to say an enveloping layer of filaments or filaments with textile bonding, which permits a good liquid exchange between absorbent / rinsing body 4 and wound environment ,
- the wound-away coating layer 10 is formed by a composite surface or - laminate, namely of a non-woven 12, preferably made
- Polypropylene and a germ-and waterproof film 14 laminated thereon, which accordingly extends over the entire planar extent of the web 12 and forms a substantially improved evaporation protection towards the side facing away from the wound.
- a partially and structured applied atraumatic coating 16 is provided on the wound-facing outside of the wound-facing coating layer 8.
- This coating is preferably a silicone coating, the coating being porous and, in the case exemplified, formed by a plurality of relatively thin strips or lines or island-shaped areas separated by uncoated areas. In these uncoated areas, the wound-facing envelope layer 8 is exposed to the wound.
- the atraumatic coating 16 forms
- Covering layer 8 can be prevented with wound tissue and on the other hand, a certain small distance between the wound-facing
- the wound dressing 2 further has a circumferentially extending edge, which are welded together by the two there
- Envelope layers 8, 10 is formed. However, the wound dressings are punched out so that the edge is largely negligible.
- the atraumatically acting coating 16 described above is not in the endless flat material of the cladding layers, but only after the last welding operation, in particular after the separation of the
- Coating material preferably with 1-component silicone from a dispensing system in the manner described above partially and structured acted upon.
- a metering device with a precisely opening needle-shaped metering nozzle is used which comprises a controlled opening and closing valve.
- Metering device is programmed in the X and Y direction and preferably also in the Z direction controlled movable. In this way, a partial and structured application, in particular with the parameters specified at the outset, for the dimensioning and the projection of the coated surface areas can be achieved.
- Ringer solution preferably applied to saturation.
- This salt-containing solution is added to a substance having an antimicrobial effect, which is cationic in the moist or moist wound environment at pH values in the slightly acidic to neutral range from pH 4 to 7.5.
- This cationic substance with antimicrobial action is attracted by negative groups of the anionic superabsorbent material in such a way that it remains bound to the superabsorbent materials even in the liquid-exchanging operation of the absorbent / rinsing body 4, ie is largely not released into the wound environment.
- germs introduced into the suction / rinsing body 4 with wound secretions are prevented from multiplying, as a result of which recontamination in the direction of the wound is largely prevented.
- the nonwoven base of the absorbent / rinsing body 4 consists of 127 g / m 2 cellulose fibers (pulp), 8 g / m 2 polypropylene / polyethylene fibers as binder fibers (in particular E-505 / FV from company Schwartswalder).
- 127 g / m 2 of the abovementioned superabsorbent polymer materials (SAP) are mixed homogeneously with this fiber mixture.
- Nonwoven base + SAP which forms the suction / rinsing body 4
- a tissue layer of cellulose in particular a basis weight of exemplarily 18 g / m 2 on each side (Diaper Tissue 1800 from Swedish Tissue AB) (in US Pat Figure not shown); however, this is not mandatory.
- the wound dressing can be designed as an example, with an exemplary
- the suction / rinsing body 4 which substantially corresponds to the dimension of the wound dressing 2, of 5.5 cm in diameter.
- the wound dressing 2 was finally activated with 13.6 ml Ringer's solution, which in the present case substantially corresponds to a saturation of the absorbent / rinsing body with liquid.
- the wrapper 6 is as previously described
- Dressing change is a very important feature, as too strong adhesion or even sticking to the wound base leads to pain during detachment and also to a renewed damage to the wound base.
- the separation force measurement described below is intended for
- the textile substrate is the wound-contacting textile
- a respective sample end is easily detached from the gelatin bed and lengthened with an adhesive tape.
- the Petri dish and the end of the tapes are clamped in the holders of the tensile testing machine and then measured the separation force.
- the withdrawal of the tensile testing machine is approximately vertical, while the respective gelatin plate / Petri dish is arranged horizontally.
- the mean separation force is evaluated over the measuring path.
- FIG. 3 shows the result of measurements on the following samples:
- Uncoated polypropylene knit and gauze were used as comparative samples.
- the silicone-coated polypropylene knit fabric is much better than wrapping the absorbent / rinsing body on the wound-facing side is suitable as gauze or
- the Applicant conducted a clinical application observation (AWB) for her wound dressing according to the invention.
- the wound dressing had the above-described composition with an atraumatically acting coating in the form of silicone in a dotted structured application with a degree of coverage of 40% of the wound-facing surface of the cladding layer 8.
- the saline-containing aqueous solution of the absorbent / rinsing body 4 was Ringer's solution with 0.1% by weight % PHMB as a cationic substance with antimicrobial action.
- average patient weight was about 77 kg, minimum 43.5 kg, maximum 122.0 kg, median 78 kg.
- the average size was 1, 69 m, minimum 1, 48 m, maximum 1, 92 m, median 1, 68 m.
- the wound causes were distributed as follows:
- the wounds were on average 5.26 ⁇ 3.08 cm long at the beginning of treatment (minimum 0.5 cm, maximum 16.0 cm, median 5.0 cm) and 3.94 ⁇
- the remaining wounds are superficial wounds.
- improved detachability / removability of the related wound dressing is attributed to the wound, which in turn is attributed to an interaction of the components of the wound dressing and as a whole positively supports wound healing.
- the wound dressing was "very good” (48.4%) or 95.3% of cases
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Medicinal Chemistry (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Materials For Medical Uses (AREA)
- Anesthesiology (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL11719527T PL2568939T3 (pl) | 2010-05-11 | 2011-05-10 | Opatrunek |
AU2011252090A AU2011252090B2 (en) | 2010-05-11 | 2011-05-10 | Wound dressing |
EP11719527.1A EP2568939B1 (de) | 2010-05-11 | 2011-05-10 | Wundauflage |
CN201180023674.8A CN102905657B (zh) | 2010-05-11 | 2011-05-10 | 创伤敷料 |
JP2013509539A JP5853019B2 (ja) | 2010-05-11 | 2011-05-10 | 創傷被覆材 |
ES11719527.1T ES2538529T3 (es) | 2010-05-11 | 2011-05-10 | Apósito |
US13/697,273 US9050443B2 (en) | 2010-05-11 | 2011-05-10 | Wound dressing |
RU2012148819/15A RU2554805C2 (ru) | 2010-05-11 | 2011-05-10 | Раневая накладка |
BR112012028923-3A BR112012028923B1 (pt) | 2010-05-11 | 2011-05-10 | Curativo para feridas |
ZA2012/09227A ZA201209227B (en) | 2010-05-11 | 2012-12-06 | Wound dressing |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102010020050.6 | 2010-05-11 | ||
DE102010020050A DE102010020050A1 (de) | 2010-05-11 | 2010-05-11 | Wundauflage |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011141454A1 true WO2011141454A1 (de) | 2011-11-17 |
Family
ID=44259993
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2011/057491 WO2011141454A1 (de) | 2010-05-11 | 2011-05-10 | Wundauflage |
Country Status (12)
Country | Link |
---|---|
US (1) | US9050443B2 (de) |
EP (1) | EP2568939B1 (de) |
JP (1) | JP5853019B2 (de) |
CN (1) | CN102905657B (de) |
AU (1) | AU2011252090B2 (de) |
BR (1) | BR112012028923B1 (de) |
DE (1) | DE102010020050A1 (de) |
ES (1) | ES2538529T3 (de) |
PL (1) | PL2568939T3 (de) |
RU (1) | RU2554805C2 (de) |
WO (1) | WO2011141454A1 (de) |
ZA (1) | ZA201209227B (de) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3040086A1 (de) | 2014-12-30 | 2016-07-06 | Paul Hartmann AG | Wundsystem |
DE102015206083A1 (de) | 2015-04-02 | 2016-10-06 | Ivf Hartmann Ag | Wundauflage zur Wundbehandlung im feuchten oder feuchtnassen Milieu |
US9561136B2 (en) | 2014-03-13 | 2017-02-07 | Gregory Troy Williams | Bandage |
EP3184124A1 (de) | 2015-12-21 | 2017-06-28 | Paul Hartmann AG | Wundsystem enthaltend zwei stoffe |
EP3184125A1 (de) | 2015-12-21 | 2017-06-28 | Paul Hartmann AG | Hydrogel enthaltendes wundsystem |
DE102015226790A1 (de) | 2015-12-29 | 2017-06-29 | Ivf Hartmann Ag | Wundauflage |
DE102016125579A1 (de) | 2016-12-23 | 2018-06-28 | Paul Hartmann Ag | Wasserhaltige Hydrogelzusammensetzung, umfassend elementare Silberpartikel |
US10555530B2 (en) | 2014-04-25 | 2020-02-11 | Flechsig Patent Company, Llc | Biocide compositions based on calcium fluoride as well as uses thereof |
EP3636233A1 (de) | 2018-10-12 | 2020-04-15 | IVF Hartmann AG | Feuchte wundauflage mit kleberand |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102012109242A1 (de) * | 2012-09-28 | 2014-04-03 | McAirlaid's Vliesstoffe GmbH | Materialbahn |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0594034B1 (de) | 1992-10-22 | 1997-01-08 | IVF Hartmann AG | Plastisch verformbare Kompresse |
WO2003039602A2 (en) | 2001-09-28 | 2003-05-15 | Quick Med Technologies, Inc. | Absorbent materials with covalently-bonded, nonleachable, polymeric antimicrobial surfaces, and methods for preparation |
US20040142019A1 (en) * | 2003-01-16 | 2004-07-22 | Xylos Corporation | Microbial-derived cellulose amorphous hydrogel wound dressing |
US20070255193A1 (en) * | 2006-04-11 | 2007-11-01 | Tyco Healthcare Group Lp | Wound dressings with anti-microbial and zinc-containing agents |
WO2008037082A1 (en) | 2006-09-25 | 2008-04-03 | Archer-Daniels-Midland Company | Superabsorbent surface-treated carboxyalkylated polysaccharides and process for producing same |
US20080082059A1 (en) | 2006-09-28 | 2008-04-03 | David Fink | Portable wound therapy system |
WO2010024928A1 (en) | 2008-08-28 | 2010-03-04 | Tyco Healthcare Group Lp | Environmentally activated compositions, articles and methods |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2192142B (en) * | 1986-07-04 | 1990-11-28 | Johnson & Johnson | Wound dressing |
GB8620227D0 (en) * | 1986-08-20 | 1986-10-01 | Smith & Nephew Ass | Wound dressing |
GB8811776D0 (en) * | 1988-05-18 | 1988-06-22 | Smith & Nephew Ass | Dressings |
PT999858E (pt) * | 1997-07-31 | 2004-12-31 | Bristol Myers Squibb Co | Penso para feridas aperfeicoado |
DE19820999A1 (de) * | 1998-05-11 | 1999-11-18 | Lohmann Therapie Syst Lts | Laminat zum Aufbringen auf einen Akzeptor |
US20010009711A1 (en) * | 1998-12-16 | 2001-07-26 | Margaret Gwyn Latimer | Resilient fluid management materials for personal care products |
GB2369997B (en) * | 2000-12-12 | 2004-08-11 | Johnson & Johnson Medical Ltd | Dressings for the treatment of exuding wounds |
US6613347B2 (en) * | 2001-02-21 | 2003-09-02 | Tolland Development Company, Llc | PVA sponge with low durometer skin silicone |
US20020137418A1 (en) * | 2001-03-23 | 2002-09-26 | 3M Innovative Properties Company | Fluid management composite |
US20030208178A1 (en) * | 2001-06-08 | 2003-11-06 | Edens Ronald L. | Labial pad having a notch |
DE10328261B4 (de) * | 2003-06-23 | 2007-10-25 | Beiersdorf Ag | Desinfizierende Auflage mit Silberbeschichtung und ihre Verwendung |
CN1809390B (zh) * | 2003-06-26 | 2010-11-17 | 株式会社瑞光 | 创伤覆盖材料和创伤覆盖材料成套器具 |
CN102783499A (zh) * | 2004-07-30 | 2012-11-21 | 金伯利-克拉克环球有限公司 | 抗微生物的装置和组合物 |
DE102004061406A1 (de) * | 2004-12-21 | 2006-07-06 | Bayer Innovation Gmbh | Infektionsresistente Polyurethanschäume, Verfahren zu ihrer Herstellung und Verwendung in antiseptisch ausgestatteten Wundauflagen |
US20060141891A1 (en) * | 2004-12-23 | 2006-06-29 | Kimberly-Clark Worldwide, Inc. | Absorbent structure with aggregate clusters |
DE102006015271A1 (de) | 2006-04-01 | 2007-10-11 | Lohmann & Rauscher Gmbh & Co. Kg | Biguanidhaltige Liposomen |
JP4783429B2 (ja) * | 2006-07-06 | 2011-09-28 | 株式会社瑞光 | 創傷被覆材 |
DE102006047041A1 (de) * | 2006-10-02 | 2008-04-10 | Birgit Riesinger | Flächenhafter Absorptionskörper |
DE102007030931A1 (de) * | 2007-07-03 | 2009-01-08 | Birgit Riesinger | Zusammensetzung, enthaltend mindestens einen nutritiven, mindestens einen desinfizierenden bzw. dekontaminierenden und/oder mindestens einen Proteasen hemmend wirkenden Wirkstoff und/oder Wirkstoffkomplex |
EP2072063A1 (de) * | 2007-12-22 | 2009-06-24 | Bayer Innovation GmbH | Infektionsresistente, auf zellulärem hydrophilem Vorpolymer basierte Polyurethanschaumstoffe, Verfahren zu ihrer Herstellung und ihre Verwendung in antiseptischen Wundverbänden |
-
2010
- 2010-05-11 DE DE102010020050A patent/DE102010020050A1/de not_active Ceased
-
2011
- 2011-05-10 ES ES11719527.1T patent/ES2538529T3/es active Active
- 2011-05-10 WO PCT/EP2011/057491 patent/WO2011141454A1/de active Application Filing
- 2011-05-10 US US13/697,273 patent/US9050443B2/en active Active
- 2011-05-10 CN CN201180023674.8A patent/CN102905657B/zh active Active
- 2011-05-10 RU RU2012148819/15A patent/RU2554805C2/ru active
- 2011-05-10 AU AU2011252090A patent/AU2011252090B2/en active Active
- 2011-05-10 PL PL11719527T patent/PL2568939T3/pl unknown
- 2011-05-10 JP JP2013509539A patent/JP5853019B2/ja active Active
- 2011-05-10 EP EP11719527.1A patent/EP2568939B1/de active Active
- 2011-05-10 BR BR112012028923-3A patent/BR112012028923B1/pt active IP Right Grant
-
2012
- 2012-12-06 ZA ZA2012/09227A patent/ZA201209227B/en unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0594034B1 (de) | 1992-10-22 | 1997-01-08 | IVF Hartmann AG | Plastisch verformbare Kompresse |
WO2003039602A2 (en) | 2001-09-28 | 2003-05-15 | Quick Med Technologies, Inc. | Absorbent materials with covalently-bonded, nonleachable, polymeric antimicrobial surfaces, and methods for preparation |
US20040142019A1 (en) * | 2003-01-16 | 2004-07-22 | Xylos Corporation | Microbial-derived cellulose amorphous hydrogel wound dressing |
US20070255193A1 (en) * | 2006-04-11 | 2007-11-01 | Tyco Healthcare Group Lp | Wound dressings with anti-microbial and zinc-containing agents |
WO2008037082A1 (en) | 2006-09-25 | 2008-04-03 | Archer-Daniels-Midland Company | Superabsorbent surface-treated carboxyalkylated polysaccharides and process for producing same |
US20080082059A1 (en) | 2006-09-28 | 2008-04-03 | David Fink | Portable wound therapy system |
WO2010024928A1 (en) | 2008-08-28 | 2010-03-04 | Tyco Healthcare Group Lp | Environmentally activated compositions, articles and methods |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9561136B2 (en) | 2014-03-13 | 2017-02-07 | Gregory Troy Williams | Bandage |
US10555530B2 (en) | 2014-04-25 | 2020-02-11 | Flechsig Patent Company, Llc | Biocide compositions based on calcium fluoride as well as uses thereof |
EP3040086A1 (de) | 2014-12-30 | 2016-07-06 | Paul Hartmann AG | Wundsystem |
WO2016107856A1 (de) | 2014-12-30 | 2016-07-07 | Paul Hartmann Ag | Wundsystem |
EP3040086B1 (de) * | 2014-12-30 | 2023-05-03 | Paul Hartmann AG | Wundsystem |
US20180071147A1 (en) * | 2015-04-02 | 2018-03-15 | Ivf Hartmann Ag | Wound dressing for wound treatment in a damp or wet environment |
WO2016156619A1 (de) | 2015-04-02 | 2016-10-06 | Ivf Hartmann Ag | Wundauflage zur wundbehandlung im feuchten oder feuchtnassen milieu |
AU2016239883B2 (en) * | 2015-04-02 | 2020-06-25 | Ivf Hartmann Ag | Wound dressing for wound treatment in a damp or wet environment |
US11000416B2 (en) | 2015-04-02 | 2021-05-11 | IVF Hartman AG | Wound dressing for wound treatment in a damp or wet environment |
DE102015206083A1 (de) | 2015-04-02 | 2016-10-06 | Ivf Hartmann Ag | Wundauflage zur Wundbehandlung im feuchten oder feuchtnassen Milieu |
EP3184125A1 (de) | 2015-12-21 | 2017-06-28 | Paul Hartmann AG | Hydrogel enthaltendes wundsystem |
EP3184124A1 (de) | 2015-12-21 | 2017-06-28 | Paul Hartmann AG | Wundsystem enthaltend zwei stoffe |
DE102015226790A1 (de) | 2015-12-29 | 2017-06-29 | Ivf Hartmann Ag | Wundauflage |
DE102016125579A1 (de) | 2016-12-23 | 2018-06-28 | Paul Hartmann Ag | Wasserhaltige Hydrogelzusammensetzung, umfassend elementare Silberpartikel |
WO2018115453A1 (de) | 2016-12-23 | 2018-06-28 | Paul Hartmann Ag | Wasserhaltige hydrogelzusammensetzung, umfassend elementare silberpartikel |
EP3636233A1 (de) | 2018-10-12 | 2020-04-15 | IVF Hartmann AG | Feuchte wundauflage mit kleberand |
WO2020074512A1 (de) | 2018-10-12 | 2020-04-16 | Ivf Hartmann Ag | Feuchte wundauflage mit kleberand |
Also Published As
Publication number | Publication date |
---|---|
RU2012148819A (ru) | 2014-06-20 |
CN102905657A (zh) | 2013-01-30 |
PL2568939T3 (pl) | 2015-08-31 |
US9050443B2 (en) | 2015-06-09 |
EP2568939B1 (de) | 2015-03-18 |
AU2011252090A1 (en) | 2012-12-13 |
JP5853019B2 (ja) | 2016-02-09 |
ZA201209227B (en) | 2013-09-25 |
JP2013526315A (ja) | 2013-06-24 |
BR112012028923A2 (pt) | 2016-07-26 |
DE102010020050A1 (de) | 2011-11-17 |
CN102905657B (zh) | 2016-05-18 |
BR112012028923B1 (pt) | 2020-05-26 |
AU2011252090B2 (en) | 2014-04-03 |
US20140163485A1 (en) | 2014-06-12 |
EP2568939A1 (de) | 2013-03-20 |
RU2554805C2 (ru) | 2015-06-27 |
ES2538529T3 (es) | 2015-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2568939B1 (de) | Wundauflage | |
US20190358361A1 (en) | Wound dressing with apertured cover sheet | |
DE19631421C2 (de) | Antimikrobielle Wundauflagen | |
EP2762177B1 (de) | Vorrichtung zur Unterdrucktherapie von Wunden | |
DE69826484T2 (de) | Verbesserter wundverband | |
EP2320844A1 (de) | Wundpflegeartikel, aufweisend einen anteil an modifizierten naturfasern oder an kunstfasern | |
WO2009019227A2 (de) | Wundpflegeartikel, aufweisend superabsorbierende polymere in faser- und/oder garnform | |
EP2153807A1 (de) | Wundpflegeartikel, aufweisend Textilbänder mit Fasern mit gelbildenden Eigenschaften sowie Fasern mit nicht gelbildenden Eigenschaften | |
EP2809363A1 (de) | Wundpflegeartikel, aufweisend mindestens eine oberfläche mit abrasiven eigenschaften | |
DE102012100842A1 (de) | Wundpflegeartikel, aufweisend mindestens eine Oberfläche mit abrasiven Eigenschaften | |
DE102007063294A1 (de) | Wundauflage enthaltend superabsorbierende Polymere | |
EP2032179B1 (de) | Wundauflage | |
DE202012012936U1 (de) | Absorbierender Hygiene- oder Pflegeartikel aufweisend einen Anteil an mindestens einemelementaren oder in Ionenform vorliegenden Schwermetall | |
EP3277239B1 (de) | Wundauflage zur wundbehandlung im feuchten oder feuchtnassen milieu | |
DE69524764T2 (de) | Wundverband, herstellung und verwendung | |
EP3040086B1 (de) | Wundsystem | |
WO2013026883A1 (de) | Bezug für einen hygiene- oder pflegeartikel | |
WO2016055483A1 (de) | Wundpflegeprodukt, aufweisend ein nanofaser-vlies | |
DE202012102259U1 (de) | Bezug für einen Hygiene- oder Pflegeartikel | |
DE102012101413A1 (de) | Flüssigkeitsdurchlässiger Primärverband aufweisend einen Anteil an Schwermetall | |
AT13770U1 (de) | Absorbierender Hygiene- oder Pflegeartikel aufweisend einen bahnförmigen Bestandteil mit einem Anteil an mindestens einem elementaren oder in ionenform vorliegenden Schwermetall |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180023674.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11719527 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011719527 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2013509539 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 9908/DELNP/2012 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2012148819 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2011252090 Country of ref document: AU Date of ref document: 20110510 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13697273 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012028923 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012028923 Country of ref document: BR Kind code of ref document: A2 Effective date: 20121112 |